ArticleInvestigational new drugs2022

Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer.

Toshiyuki Sumi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.